Astria Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Perceptive Advisors and related entities have reported zero beneficial ownership in Astria Therapeutics following its acquisition by BioCryst.
Magnetar Financial and its affiliates report the cancellation of all 3.43 million Astria Therapeutics shares following the company's merger at $8.55 per share.
Magnetar Financial and its affiliates have reported a 5.87% beneficial ownership in Astria Therapeutics, Inc., acquired for merger arbitrage purposes following the BioCryst merger announcement.
SCHEDULE: Perceptive Backs Astria-BioCryst Merger
Perceptive Advisors and its affiliates have entered into a voting agreement to support BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.